Nghĩa của từ myeloid bằng Tiếng Sec
myeloidní Entry edited by: B2
Đặt câu có từ "myeloid"
1. She is suffering from myeloid leukemia.
2. Method of treating myeloid leukemias
3. Six months later, she comes back with acute myeloid leukemia.
4. Large granular lymphocytic leukemia Coexists with myeloid clones and myelodysplastic syndrome
5. In 2006, Brown was diagnosed with acute myeloid leukemia (AML).
6. Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors
7. Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia
8. This study was conducted in # anaemic patients with non-myeloid malignancies receiving multi-cycle chemotherapy
9. Methods of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia
10. Cytogenetics is considered one of the most valuable prognostic determinants in acute myeloid leukemia (AML)
11. 17 Electronmicroscope observation revealed an extensive vacuolization in proximal tubular cells and formation of myeloid bodies in lysosome.
12. Diagnosis and classification of acute myeloid leukemia (AML) is based on cytological criteria and cytogenetic alterations.
13. The majority of patients with acute myeloid leukemia (AML) are over 60 years of age at diagnosis.
14. Chronic myeloid leukemia - a higher Basophil percentage at diagnosis is associated with a significantly decreased probability of survival
15. Basophils differentiate from myeloid stem cells under the influence primarily of IL-3 and other, as yet unidentified, cytokines
16. Archpriest Steven John Belonick reposed in the Lord Jesus Christ on August 7, 2019, after an extended illness, acute myeloid leukemia
17. Cemic and Aleucemic tumor-like proliferative processes involving the lymphoid system; myeloid leucosis, those that involve myelocytes and their precursors
18. Acute myeloid leukemia (AML) starts in the bone marrow -- the spongy tissue inside your bones where blood cells are made
19. 15 Objective To explore the clinical and biological characteristics of 12 cases oft (8; acute myeloid leukemia with sex chromosome loss.
20. Plasmacytoid Dendritic Cells Proliferation Coexisted with Acute Myeloid Leukemia Their discovery means that archaic humans survived--and even Coexisted with H
21. Preclinical findings show that IMGN632, which Alkylates DNA, had potent selective activity against AML cells with lower cytotoxicity to normal myeloid progenitor cells than …
22. In addition, the strongest associations of Benzene and cancer risk are found with risk of acute myeloid leukemia and non-Hodgkin’s lymphoma
23. While the extramedullary collection of leukemic cells is generally regarded as myeloid sarcoma (previously chloroma/granulocytic sarcoma), leukemia Cutis is a generic term to …
24. Areg is a proinflammatory mediator of GN via ( 1 ) enhancing renal pathogenic myeloid cell infiltration and ( 2 ) direct effects on M/M polarization, proliferation, and cytokine secretion
25. Allergin-1 inhibits IgE-mediated, mast cell–dependent anaphylaxis in mice and is expressed in myeloid cells (dendritic cells and macrophages) and on mast cells
26. Acute promyelocytic leukemia (APL) is an aggressive type of Acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow
27. Clonal hematopoiesis (CH) refers to a genetically distinct subpopulation of myeloid cells that share an acquired (ie, not inherited) mutation, which distinguishes them from other tissues and unaffected hematopoietic cells
28. Bewry, Nadine N., "STAT3 Contributes to Resistance Towards BCR-ABL Inhibitors in a Bone Marrow Microenvironment Model of Drug Resistance in Chronic Myeloid Leukemia Cells" (2009)
29. The present invention relates to a pharmaceutical composition for treating chronic myeloid leukemia, containing a Liriodendron tulipifera L. bark extract as an active ingredient, and more specifically, to a pharmaceutical composition for treating chronic myeloid leukemia, containing a Liriodendron tulipifera L. bark extract, which causes cell death by a change in mitochondrial membrane potential (MMP) in leukemia cells, and the cleavage of poly(ADP-ribose) polymerase (PARP) and caspase-3 related to a cell death pathway, in order to selectively inhibit the T315I mutant enzyme generated by the mutation of the BCR-ABL fusion gene, which is a gene causing chronic myeloid leukemia.
30. Panels show donor-derived total Chimerisms (D), Chimerisms of lymphoid lineage (E and F), and Chimerisms of myeloid lineage (G) in PB at the indicated time points after transplantation
31. (Chromaffin cell, NLM, Medical Subject Headings) An acute myeloid leukemia with monocytic and granulocytic differentiation and the presence of a Characteristically abnormal eosinophil component in the bone marrow.
32. MyeloBlastoma: [ mi″ĕ-lo-blas-to´mah ] a focal malignant tumor composed of myeloblasts or early myeloid precursors occurring outside of the bone marrow; observed in acute myelogenous leukemia .
33. The present invention relates to a pharmaceutical dosage form for treating chronic myeloid leukemia, containing a Liriodendron tulipifera L. bark extract as an active ingredient, and more specifically, to a pharmaceutical dosage form for treating chronic myeloid leukemia, containing a Liriodendron tulipifera L. bark extract, which causes cell death by a change in mitochondrial membrane potential (MMP) in leukemia cells and the cleavage of poly(ADP-ribose) polymerase (PARP) and caspase-3 related to a cell death pathway, in order to selectively inhibit the T315I mutant enzyme generated by the mutation of the BCR-ABL fusion gene, which is a gene causing chronic myeloid leukemia.
34. In the cultivation of leukemic cells (4 cases of chronic lymphadenosis, 1 acute monocytic leukemia, 1 chronic myeloid leukemia) a distinctive increase in cells can be seen following the influence of Phaseolin.
35. These cases of CMPD break down into the main groups as follows: CML 23.2 %, megakaryocytic myelosis consistent with agnogenic myeloid metaplasia 22.3 %, essential thrombocythemia 22.1 %, and polycythemia vera 20.4 %; 12.0 % of cases were unclassifiable.
36. When added at sublethal concentrations, the methylation inhibitors had little or no effect on c-myc, v-fos, histone H2B, or actin expression, nor did any significant number of the drug-treated cells demonstrate myeloid characteristics.
37. A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (Culminate) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
38. These findings demonstrate that NOTCH-mediated Arterialization of HE is an essential prerequisite for establishing definitive lympho-myeloid program and suggest that exploring molecular pathways that lead to arterial specification may aid in vitro approaches to enhance definitive hematopoiesis from hPSCs.
39. Blood capillaries in the composition of the hepatic lobule run: +between girders -inside hepatic girder -between hepatic Acinuses -between hepatic acinus and girder ? Stromal component of lymph nodes consists of: +reticular cells, collagenous and reticular fibers, macrophages -reticular cells, adipocytes, megakariocytes -cells myeloid and
40. Basophil differentiation from myeloid progenitors is driven by IL-3 and their expression of IL-3R αchain (also known as CDw123) enables them to be distinguished from mast cells.Basophils make up less than 1% of leukocytes in humans but they are the only circulating leukocytes that
41. 15 Jul 2020 Arog Pharmaceuticals completes a phase I/II trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02400281) 15 Jul 2020 Crenolanib is still in phase I trials for Oesophageal cancer and Gastric cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination
42. Examine whether a combination of decitabine given for 10 days (days 1-10), rather than the usual 5 days, plus "standard dose cytArabine (ara-C) (100 mg/m^2 daily days 1-7) might improve 6-month survival probability from the historical 65% to 80% in patients age >= 60 with newly diagnosed acute myeloid leukemia (AML).